Mark E. Bunnage

Companies

• Vertex PharmaceuticalsEVP, Chief Scientific Officer Feb 3, 2026 to now¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Vertex Pharmaceuticals VRTX7,284 shares²$3.8M at $525.12May 15, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• May 15, 2026Sold 33 shares at $453.45 of Vertex Pharmaceuticals²
• Feb 25, 2026Sold 620 shares at $486.35 of Vertex Pharmaceuticals³
• Feb 24, 2026Shares withheld for tax 582 shares at $485.11 of Vertex Pharmaceuticals³
• Feb 18, 2026Sold 1,182 shares at $473.68 of Vertex Pharmaceuticals⁴
• Feb 17, 2026Sold 2,437 shares at $489.46 of Vertex Pharmaceuticals⁴
• Feb 17, 2026Shares withheld for tax 1,110 shares at $483.75 of Vertex Pharmaceuticals⁴
• Feb 17, 2026Granted 2,584 shares of Vertex Pharmaceuticals⁴
• Feb 13, 2026Shares withheld for tax 2,283 shares at $487.76 of Vertex Pharmaceuticals⁵
• Feb 11, 2026Sold 2,021 shares at $460.43 of Vertex Pharmaceuticals⁶
• Feb 10, 2026Shares withheld for tax 1,127 shares at $468.41 of Vertex Pharmaceuticals⁶